The Q1 results are largely noise — the revenue swing reflects the lumpy nature of biotech collaboration milestones, not operational deterioration. The key catalyst is the CNTY-813 IND submission in Q4 2026 and the ADA presentation on June 8, 2026. Monitor for any data readouts or regulatory updates that could move the stock.
Price Chart
Executive Summary
Century Therapeutics reported Q1 2026 results with a net loss of $21.6M vs net income of $76.6M in Q1 2025, driven by the absence of collaboration revenue ($0 vs $109.2M) after the Bristol-Myers Squibb agreement milestone was recognized in the prior year. The company highlighted pipeline progress for CNTY-813 (type 1 diabetes) and CNTY-308 (autoimmune), and ended the quarter with $217M in cash, extending runway into Q1 2029.
Key Financial Metrics
Key Facts
- Net loss of $21.6M in Q1 2026 vs net income of $76.6M in Q1 2025
- Collaboration revenue dropped to $0 from $109.2M in Q1 2025 (Bristol-Myers Squibb milestone completed)
- Cash, cash equivalents, and marketable securities of $217.0M as of March 31, 2026
- Cash runway extended into Q1 2029
- R&D expenses decreased to $17.1M from $26.6M YoY
- G&A expenses decreased to $6.6M from $8.4M YoY
- CNTY-813 IND submission on track for Q4 2026; initial clinical data expected in H2 2027
- CNTY-308 on track to enter clinic in 2026
- Weighted average diluted shares outstanding increased to 193.5M from 86.1M YoY (post January 2026 $135M private placement)
Financial Impact
Net loss of $21.6M vs net income of $76.6M YoY; revenue $0 vs $109.2M YoY; cash position $217.0M
Risk Factors
- No near-term revenue catalysts until CNTY-813 enters clinic (H2 2027)
- Dilution from January 2026 $135M private placement (shares outstanding more than doubled)
- Preclinical/clinical failure risk for CNTY-813 and CNTY-308
- Cash burn rate of ~$25M/quarter in operating cash flow
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-059824 |
| Document: tm2614312d1_8k.htm | 0001104659-26-059824 |
| Document: 0001104659-26-059824-index-headers.html | 0001104659-26-059824 |
| Document: 0001104659-26-059824-index.html | 0001104659-26-059824 |
| Document: 0001104659-26-059824.txt | 0001104659-26-059824 |
| 8-K Data (Synthetic) | 0001104659-26-059824 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 25d ago | 8-K | $1.53 $1.48 | ▼ −3.27% | ▼ −3.94% | $1.48 (−3.59%) |
Oct 2, 2026 25d ago | Press Release | $1.53 $1.48 | ▼ −3.27% | ▼ −3.94% | $1.48 (−3.59%) |
Sep 22, 2026 4w ago | Institutional Cluster | $1.89 $1.76 | ▼ −6.88% | ▼ −6.16% | $1.48 (−21.96%) |
Sep 10, 2026 6w ago | 3 | $1.94 $2.00 | ▲ +3.09% | ▲ +3.54% | $1.48 (−23.97%) |
Aug 12, 2026 10w ago | 8-K | $1.96 $1.93 | ▼ −1.53% | ▼ −2.23% | $1.48 (−24.74%) |
Aug 12, 2026 10w ago | Press Release | $1.96 $1.93 | ▲ +1.53% | ▲ +2.23% | $1.48 (+24.74%) |
Jun 16, 2026 18w ago | 8-K | $2.25 $2.29 | ▲ +1.78% | ▲ +1.00% | $1.48 (−34.44%) |
Jun 15, 2026 19w ago | Insider Cluster | $2.18 $2.25 | ▲ +3.21% | ▲ +4.46% | $1.48 (−32.34%) |
Jun 9, 2026 19w ago | Insider Cluster | $2.12 $2.24 | ▲ +5.66% | ▲ +3.96% | $1.48 (−30.42%) |
Jun 9, 2026 19w ago | Insider Cluster | $2.12 $2.24 | ▲ +5.66% | ▲ +3.96% | $1.48 (−30.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers